Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 6Phase 3 5Phase 1 2Phase NA 1

Status

Completed 25Terminated 4Active not recruiting 4Unknown 3Withdrawn 2Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × selinexor × Clear all
NCT07200102 2026-03-23

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Washington University School of Medicine

Phase 1 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma

NCT06225310 2025-01-16

KPT-IST-391

Oncotherapeutics

Phase 1 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡